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Defensins constitute a major class of cationic antimicrobial peptides in mammals and vertebrates,
acting as effectors of innate immunity against infectious microorganisms. It is generally accepted
that defensins are bactericidal by disrupting the anionic microbial membrane. Here, we provide evi-
dence that membrane activity of human a-defensins does not correlate with antibacterial killing.
We further show that the a-defensin human neutrophil peptide-1 (HNP1) binds to the cell wall pre-
cursor lipid II and that reduction of lipid II levels in the bacterial membrane signiﬁcantly reduces
bacterial killing. The interaction between defensins and lipid II suggests the inhibition of cell wall
synthesis as a novel antibacterial mechanism of this important class of host defense peptides.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Defensins form a large subfamily of cationic antimicrobial pep-
tides that kill a broad range of microorganisms [1–4]. Human
defensins are cysteine-rich, cationic peptides with molecular
masses ranging from 3 to 5 kDa. Based on the connectivity of the
six conserved cysteine residues and sequence homology, human
defensins are classiﬁed into a and b families. Both families of
defensins have similar three-dimensional structures as determined
by X-ray crystallography and NMR studies [5–9], sharing a com-
mon fold of three-stranded anti-parallel b-sheets constrained by
three intra-molecular disulﬁde bonds. Human defensins were dis-
covered originally as natural peptide antibiotics in neutrophils.
These defensins were named human neutrophil peptides (HNP)
1–3 of the a-defensin family [10]. Subsequently, a fourth a-defen-
sin was discovered in neutrophils, termed HNP-4 [11–13]. More re-
cently, two additional a-defensins were described, termed human
defensin 5 and 6 [14,15]. HD-5 and HD-6 are stored in the granules
of Paneth cells, specialized epithelial cells in the small intestine
[16].lf of the Federation of European Bi
(E. de Leeuw), wlu@ihv.Defensins are widely accepted to kill bacteria through pore for-
mation in the microbial membrane, causing leakage of intracellular
contents and cell lysis [17,18]. The speciﬁc disruption of the bacte-
rial membrane by defensins is believed to be driven by electro-
static attractions between these cationic peptides and the
negatively charged membrane. However, alternative mechanisms
for bacterial killing have been proposed, including membrane-
independent mechanisms and targeting of intracellular com-
pounds by defensins [19–21].
Recent observations on the bacterial killing by human defensins
could not fully be explained by the membrane-disruption model,
suggesting a more nuanced mode of action. First, a-defensins were
shown to preferentially kill Gram-positive bacteria, whereas b-
defensins kill Gram-negative strains more effectively [22,23]. How-
ever, human b-defensins carry more positive charges, indicating
that cationicity of defensins alone does not explain this strain-
speciﬁcity. Second, disruption of the membrane via stable pore for-
mation is believed to require peptide structure. However, we and
others have shown that bacterial killing by defensins can be
structure-independent [24,25]. Third, we recently observed that
a-defensins composed entirely of D-amino acids show greatly re-
duced antibacterial activity against Staphylococcus aureus com-
pared to the L-peptide, suggesting that the microbial membrane
is not the sole target [26]. Here, we further examine the bacterial
killing by a-defensins and provide evidence for an interaction with
the bacterial target lipid II.ochemical Societies.
1544 E. de Leeuw et al. / FEBS Letters 584 (2010) 1543–15482. Materials and methods
2.1. Materials
Chemicals used for solid phase peptide synthesis were obtained
as described [27]. S. aureus ATCC 29213 was obtained from
Microbiologics (St. Cloud, MN). The phospholipids palmitoyl–
oleoyl-phosphatidylcholine (POPC), palmitoyl–oleoyl-phosphati-
dylglycerol (POPG) and dipalmitoyl–phosphatidyl choline (DPPC)
were purchased from Avanti Polar Lipids (Alabaster, AL). 8-Amino-
naphthalene-1,3,6-trisulfonic acid sodium salt (ANTS) and p-xyl-
enebis(pyridinium) bromide (DPX) were from Molecular Probes
(Eugene, OR). Poly-L-lysine (MW = 3800) was obtained from Sigma.
Bacitracin, D-cycloserine and fosfomycine were purchased from
Sigma, Calbiochem and LKT Laboratories respectively.
2.2. Solid phase peptide synthesis
Chemical synthesis and folding of defensins was carried out as
described [27,28]. The molecular mass of the peptides was veriﬁed
by electrospray ionization mass spectrometry (ESI–MS) as de-
scribed [27]. Peptide stock solutions prepared with water were
quantiﬁed spectroscopically using molar extinction coefﬁcients at
280 nm calculated according to the algorithm of Pace et al. [29].
2.3. LUVs preparation
LUVs with the low molecular weight ﬂuorophore/quencher pair
(ANTS/DPX) encapsulated were prepared using the standard extru-
sion method. Speciﬁcally, phospholipids were dissolved in chloro-
form at a desired molar ratio, dried as a ﬁlm by solvent
evaporation. After removal of residual solvent, the lipid ﬁlm was
hydrated in the ﬂuorescent solution containing 5 mM HEPES,
12.5 mM ANTS, 45 mM DPX, and 20 mM NaCl, pH 7.0, freeze–
thawed for 10 cycles and extruded 10 times through 0.4-lm poly-
carbonate membranes. LUVs were separated from unencapsulated
materials by gel ﬁltration chromatography using a Sepharose CL-
4B column eluted with 5 mM HEPES, 100 mM NaCl, pH 7.4 (high-
salt). For leakage assays in a low-salt buffer, puriﬁed vesicles were
further diluted with 5 mM HEPES containing 10 mM NaCl, pH 7.4.
2.4. Leakage assay
Leakage of ANTS from LUVs, monitored on a LS-55 Perkin Elmer
luminescence spectrometer, was characterized by an increase in
ﬂuorescence, which was quenched by DPX when encapsulated to-
gether inside liposomes [30]. 270 ll ANTS/DPX-encapsulated LUVs
(in either high-salt or low-salt buffers) were added to each well of
a 96-well plate to a ﬁnal lipid concentration of 600 lM. 30 ll H2O
was added to the ﬁrst well of each row as a blank, and 30 ll 2.5%
(v/v) Triton X-100 to the last (twelfth) well as the control for 100%
leakage. Upon addition of 30 ll of a twofold dilution series of defen-
sin, the ﬂuorescence signal was recorded at 515 nm with an excita-
tionwavelength of 353 nm, 10 nmbandwidths and a 390 nmcut-off
ﬁlter in the emission path. Percent leakage is expressed as:
%leakage ¼ ððFt  F0Þ=ðF100  F0ÞÞ  100
where Ft is the ﬂuorescence determined at different time points
after addition of defensin, F0 is the background ﬂuorescence of the
‘‘blank” cells, and F100 is the ﬂuorescence of the control cells con-
taining 0.25% Triton X-100.
2.5. Lipid II puriﬁcation
Short-chain water-soluble lipid II containing a lipid tail of three
isoprene units was generated and puriﬁed essentially as described[31]. Typically, M. ﬂavus vesicles (120 lmol lipid-Pi) were incu-
bated together with 500 lmol UDP-GlcNAc, 500 lmol UDP-Mur-
NAC-pentapeptide and 400 lmol farnesyl phosphate in 100 mM
Tris–HCl pH 8.0, 5 mM MgCl2. The incubation lasted 2 h at room
temperature for 3-P. The synthesis of 3-lipid II was followed using
RP-8 reversed phase TLC (Merck) developed in 75% methanol. For
puriﬁcation, the membranes were removed by centrifugation at
40 000g and the supernatant was collected and loaded on a C18
HPLC column and eluted with a linear gradient from 50 mM
ammonium bicarbonate to 100% methanol in 30 min. Farnesyl-li-
pid II (3-lipid II) eluted at approximately 60% methanol. Its identity
was conﬁrmed by mass spectroscopy.
2.6. Surface plasmon resonance
Surface plasmon resonance binding experiments were carried
out on a BIAcore T100 system (BIAcore Inc., Piscataway, NY) at
25 C. The assay buffer was 10 mM HEPES, 150 mM NaCl, 0.05%
surfactant P20, pH 7.4 (±3 mM EDTA). L-HNP1 (780 RUs) or D-
HNP1 (790 RUs) were immobilized on CM5 sensor chips using
the amine-coupling chemistry recommended by the manufacturer.
Lipid II was introduced into the ﬂow-cells at 30 ll/min in the run-
ning buffer. Association and dissociation were assessed for 300 and
600 s, respectively. Resonance signals were corrected for non-spe-
ciﬁc binding by subtracting the background of the control ﬂow-
cell. After each analysis, the sensor chip surfaces were regenerated
with 15 mMHCl for 30 s at a ﬂow rate 100 ll/min, and equilibrated
with the buffer prior to next injection. Binding isotherms were
analyzed with manufacturer-supplied software for BIAcore T100
and/or GraphPad Prism 4.0.
2.7. Antibacterial activity assay
The antibacterial activity of HNP1 against S. aureus ATCC 29213
was carried out in a 96-well turbidimetric assay essentially as de-
scribed previously [22]. Lipid II levels in S. aureus were manipu-
lated by the addition of three different inhibitors of cell wall
synthesis: bacitracin (250 lg/ml), D-cycloserine (64 lg/ml) and
fosfomycine (250 lg/ml). Bacterial cultures were pre-treated with
these compounds for 30 min under shaking at 37 C. Subsequently,
cells were exposed to HNP1 peptide ranging from 256 to 1 lg/ml
for 15 min, after which HNP1 activity was neutralized by the addi-
tion of Mueller Hinton broth. Bacterial growth was monitored for
12 h and data were analyzed as described [22].3. Results
3.1. Membrane lipid interaction of a-defensins
Defensins are believed to kill bacteria by permeabilizing the
membrane, causing leakage of intracellular content and eventually
cell lysis and death. We tested the ability of six human a-defensins
to induce leakage of ﬂuorophores encapsulated in LUVs (Fig. 1).
Fig. 1 shows typical time-dependent leakage curves for HNP1–4
and HD-5–6 with POPG LUVs at high and low-salt concentrations
over a period of 24 h. All the six a-defensins tested at concentra-
tions ranging from 0.19 to 100 lg/ml, whenever capable of
inducing liposomal leakage, were fast acting as evidenced by a
ﬂuorescence plateau reached within the ﬁrst hour. The plateau ef-
fect reﬂects the observation that at the start of the experiment the
fractional ﬂuorescence increases rapidly due to leakage of ANTS
and DPV from the vesicles into the exterior solution, after which
dilution removes the quenching effect of DPX. The observed differ-
ences between individual defensins over time likely reﬂect differ-
ences in the kinetics of induction of LUV leakage. Membrane
Fig. 1. Time-dependent percent release of ANTS-DPX from POPG LUVs induced by the six human a-defensins at 10 lg/ml over a period of 24 h (circle = HNP1, cross = HNP2,
triangle = HNP3, diamond = HNP-4, star = HD-5, square = HD6). (A) At high-salt concentration (5 mM HEPES, 100 mM NaCl, pH 7.4). (B) At low-salt concentration (5 mM
HEPES, 10 mM NaCl, pH 7.4). LUVs were 250 nm in diameter and 600 lM (phospholipids) in concentration.
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tions and varied signiﬁcantly between the defensins tested.
Next, we examined the effects of negative surface charge on
defensin-induced membrane leakage. We used HNP1, extensively
in our laboratory [23,26,32,33], as a model for a-defensins in
these experiments. To elucidate the role of electrostatic forces in
defensin-induced membrane leakage, we prepared LUVs com-
posed of the unsaturated lipid pair POPC (charge: 0) and POPG
(charge: 1) at four different ratios, i.e., POPC:POPG = 1:0, 3:2,
2:3, and 0:1. As shown in Fig. 2A, leakage from LUVs became
increasingly pronounced across the entire HNP1 concentration
range as the content of the negatively charged lipid POPG in-
creased from 0%, 40%, 60% to 100%, equivalent to a charge on
the membrane surface of 0, 0.4, 0.6 and 1, respectively. LUVs
composed solely of the neutral lipid POPC were resistant to the at-
tack by HNP1 at all concentrations used, regardless of the incuba-
tion time. We recently reported that HNP1 composed entirely of
D-amino acids (D-HNP1) was signiﬁcantly less bactericidal than
L-HNP1 against S. aureus [26]. We compared the ability of both
L- and D-HNP1 to induce leakage from LUVs (DPPC/POPG (1:1))
and no signiﬁcant difference in activity between the two enantio-
mers was found (Fig. 2B).Fig. 2. (A) Effects of surface charge on HNP1-induced leakage from LUVs of four differen
charge = 0.4), POPC/POPG = 2:3 (triangle, surface charge = 0.6), and POPG (diamond, su
D-HNP1 (squares). A twofold dilution series of HNP1 peptides from 0.19 to 100 lg/ml wa
indicate the standard error in triplicate experiments.Taken together, these ﬁndings suggest that defensin-induced
permeabilization of lipid vesicles depends on electrostatic interac-
tion, however varies greatly between different a-defensins. Most
importantly, the ability of individual a-defensins to cause mem-
brane leakage (Fig. 1) correlates poorly with their ability to kill bac-
teria [22]. For example, HNP-4, the most membrane active defensin
in the panel of six (Fig. 1), is ineffective against Gram-positive bac-
teria [22]. Vice versa, HNP1 and HD-5 are potently bactericidal,
however display reduced, or in the case of HD-5 little membrane
activity even at high concentrations. Finally, our observation that
D-HNP1 and L-HNP1 disrupt LUVs equally efﬁciently suggests that
native HNP1 preferentially interacts with a bacterial membrane
component, possibly of chiral nature.
3.2. HNP1 binds to lipid II
Recently, a-defensins were shown to bind with high afﬁnity to
glycosylated proteins [34] and carbohydrates [35]. HNP1 kills
Gram-positive bacteria very efﬁciently, however showed reduced
membrane leakage, especially at high-salt concentrations. Based
on these studies, we reasoned that defensins could interact with
components of the bacterial cell wall or cytoplasmic membrane.t compositions: POPC (circle, surface charge = 0), POPC/POPG = 3:2 (square, surface
rface charge = 1). (B) LUV (POPG:DPPC 1:1) leakage induced by L-HNP1 (circles) or
s incubated with 600 lM LUVs for one hour before readings were taken. Error bars
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Fig. 4. Lipid II-dependent bacterial killing by HNP1. Survival curves of S. aureus
ATCC 29213 exposed to HNP1 at concentrations varying twofold from 1 to 256 lg/
ml. Bacteria were pre-treated with bacitracin (250 lg/ml), D-cycloserine (64 lg/ml)
and fosfomycine (250 lg/ml) for 30 min under shaking at 37 C as indicated,
followed by exposure to HNP1 for 15 min. Each curve is the mean of three separate
experiments (±S.D.). Points scored as zero survival could not be plotted.
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lipid II, a peptidoglycan precursor, for two reasons: (i) the Gram-
positive cell wall consists of a thick layer of peptidoglycan and
(ii) lipid II is a known target for antibiotic peptides [36]. D-HNP1
and a linear form of HNP1 were studied also, since both linear as
well as enantiomeric a-defensin peptides appeared less bacterici-
dal against S. aureus, but equally bactericidal against E. coli
[24,26]. We used a surface plasmon resonance (SPR) approach to
determine the binding of HNP1 to lipid II directly. Initial binding
of L-HNP1, D-HNP1 and linear HNP1 to soluble lipid II immobilized
on the chip surface was determined. As shown in Supplementary
Fig. 1, linear HNP1 showed little or no binding to lipid II at 0.1, 1
or at 10 lM. Both L- and D-HNP1 bound lipid II dose-dependently,
however binding of wild-type HNP1 was more efﬁcient than that
of the D-form. Conversely, the L- and D-HNP1 peptides were indi-
vidually immobilized on a CM5 chip and binding of the puriﬁed,
soluble form of lipid II ranging in concentration from 25 to
0.78 lM to both peptides was determined. As shown in Fig. 3,
soluble lipid II bound to both the L-form as well as the D-form of
HNP1. Fitting of the kinetic data to a 1:1 binding model indicated
that lipid II binds the L-HNP1 peptide with an approximately ﬁve
times higher afﬁnity than the D-peptide (2.19  106 M vs.
1.08  105 M).
3.3. HNP1 functionally interacts with lipid II
To examine whether the observed interaction between HNP1
and lipid II is functionally relevant in the environment of the mem-
brane, we determined the ability of HNP1 to kill S. aureus with al-
tered levels of lipid II. Three different inhibitors of cell wall
synthesis, fosfomycine, D-cycloserine, and bacitracin, were used
to reduce the lipid II levels in S. aureus cells. Bacitracin binds di-
rectly to undecaprenyl-pyrophosphate, the portion of lipid II that
remains in the membrane once GlcNAc–MurNAc is polymerized,
and prevents its use in subsequent cycles of lipid II synthesis. Fosf-
omycine is an inhibitor of MurA, the enzyme responsible for the
ﬁrst step in peptidoglycan synthesis. D-Cycloserine inhibits both
alanine racemase and D-Ala–D-Ala ligase, two enzymes required
for the synthesis of the D-Ala–D-Ala dipeptide of lipid II. All three
inhibitors thus block the synthesis of lipid II [37]. S. aureus cells
were exposed to each of the lipid II synthesis inhibitors for
30 min and subsequently exposed to HNP1 at concentrations rang-
ing from 256 to 1 lg/ml for 15 min (Fig. 4). Following pre-treat-
ment with lipid II biosynthesis inhibitors and exposure of HNP1
to the bacteria for 2 h, according to our original protocol [22], we
observed no difference in bacterial killing (data not shown). Most
likely, the effects of any bacterial pre-treatments are negated byFig. 3. Binding kinetics of soluble lipid II on immobilized HNP1 as determined by SP
experiments of soluble lipid II (from 20 to 0.390625 lM) using a sensorchip with 780
represent the average of the two separate experiments (individual values: L-HNP1: 1.79killing efﬁciency and kinetics of HNP1 during the prolonged, 2 h
exposure to the bacteria. As observed previously, after 15 min,
HNP1 efﬁciently killed S. aureus [38]. At peptide concentrations
of 256 and 128 lg/ml, bacterial growth did not measurably recover
after 12 h incubation and data points could not be plotted. Fosf-
omycine and D-cycloserine and in particular bacitracin treatment
attenuated killing of S. aureus by HNP1 markedly. Taken together,
these data indicate that efﬁcient killing of S. aureus by HNP1 de-
pends on membrane lipid II levels.
4. Discussion
Disruption of the functional integrity of the bacterial membrane
is a commonmodeof action ofmany antibacterial compounds and is
believed to be the primarymode of bacterial killing by defensins. An
early study reported on the bactericidal activity of HNP1-3 against
E. coli, suggesting a sequential permeabilization of the outer and in-
ner membranes [18]. More recent observations on the bactericidal
activity of a-defensins have expanded and nuanced these ﬁndings.
We and others reported that linear, unstructured defensins retained
their antibacterial activity in a strain-selective manner [24,39]. The
activity of HD-5 against E. coli appeared structure-independent,
whereas the unstructured peptide showed greatly reduced activity
against S. aureus [24]. More recently, we observed that the D-forms
of HNP1 and HD-5 were signiﬁcantly less active than their nativeR at room temperature. Representative sensorgrams of one out of two separate
RUs of L-HNP1 (left panel) or 790 RUs of D-HNP1 (right panel). Indicated Kd values
 106 and 2.59  106; D-HNP1: 1.11  105 and 1.05  105 respectively).
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Combined, these ﬁndings suggested different bactericidal mecha-
nisms of a-defensins against E. coli or S. aureus. In addition, these
ﬁndings suggested a possible interaction between defensins and
an unidentiﬁed cellular component of S. aureus.
In this study, we ﬁnd that HNP1 functionally interacts with lipid
II, an essential precursor of cell wall synthesis [36]. A number of
antibacterial compounds target lipid II, thus affecting cell wall syn-
thesis or membrane function [36]. For example, the antibacterial
action of nisin, an amphiphilic peptide produced by certain strains
of Lactococcus lactis, is a result of its high afﬁnity for lipid II as well
as its ability to assemble into nisin–lipid II complexes [31]. Such
complexes have the ability to form pores in the membrane,
explaining the high efﬁcacy of nisin [40]. Here, we show that bac-
terial killing by a-defensins depends on lipid II levels by blocking
the synthesis of lipid II. All three lipid II synthesis inhibitors re-
duced bacterial killing, in particular when S. aureus cells were
pre-treated with bacitracin. A similar observation was made re-
cently in the case of nisin [37]. In this study, depolarization of
the S. aureus membrane induced by nisin was suppressed by pre-
treatment of cells with lipid II inhibitors, especially by bacitracin.
Interestingly, nisin and bacitracin share a common target in bind-
ing the lipid II molecule, both binding the pyrophosphate moiety of
undecaprenyl-pyrophosphate [37,40]. Since the antibacterial activ-
ity of both nisin and defensin was reduced most strongly by treat-
ment with bacitracin, it is tempting to speculate that defensins,
like nisin, may use lipid II as an initial binding target and perhaps
even similarly disrupt the membrane via complex pore formation.
Our observation that HNP1 binds to lipid II partly rationalizes
our previous ﬁndings on the strain-selective and structure-depen-
dent difference in bactericidal activity of human a-defensins. How-
ever, questions still remain why a-defensins preferentially kill
Gram-positive bacteria. For example, we found that D-HNP1 binds
to lipid II with a ﬁvefold weaker afﬁnity than the L-form. This dif-
ference could be explained by the fact that lipid II itself is a chiral
molecule. However, D-HNP1 was found to be 19 times weaker in
S. aureus killing compared to L-HNP1 as judged by their respective
vLD90 values, deﬁned as the defensin concentration required to kill
90% of bacteria [26]. Defensins therefore may interact with other
membrane components in addition to lipid II. Other possible inter-
actions at the bacterial membrane could include negatively
charged molecules such as (lipo)teichoic acid in the case of
Gram-positive bacteria or lipopolysaccharide or teichoic acid in
the case of Gram-negative bacteria. Precursors of teichoic acid syn-
thesis are, like lipid II, undecaprenyl-linked [41], and may therefore
constitute a possible binding target for HNP1 also. In addition, we
observed that bacterial killing by a-defensins correlates poorly
with their lipid membrane activity. Nevertheless, increase of nega-
tive charge of the phospholipid headgroup increased HNP1 mem-
brane activity, suggesting that bactericidal activity may involve
direct defensin–lipid interactions. In summary, our ﬁndings sug-
gest the inhibition of peptidoglycan synthesis through binding of
lipid II as a novel mechanism of bacterial killing for defensins.
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